SCHEMBL6990964

SCHEMBL6990964

O=C1Nc2ccc(F)cc2Nc2sc3cc(F)ccc3c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
BCKDK O14874 1/20 0.35
CDK2 P24941 2/20 0.35
CCNE2 O96020 1/20 0.35
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CCNE1 P24864 1/20 0.35
CAMK2B Q13554 1/20 0.35
CAMK2G Q13555 1/20 0.35
CAMK2D Q13557 1/20 0.35
CAMK2A Q9UQM7 1/20 0.35
LRRK2 Q5S007 2/20 0.34
CASP3 P42574 1/20 0.34
ESR1 P03372 2/20 0.33
TGM2 P21980 1/20 0.33
MIF P14174 1/20 0.33
MPI P34949 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6992702 0.92 TGM2 (0.37) MAPTALDH1A1LMNAPOLBCDK2
SCHEMBL6997151 0.91 CCNE2 (0.40) MAPTALDH1A1LMNAPOLBBCKDK
SCHEMBL6998266 0.91 CSNK1G1 (0.38) MAPTALDH1A1LMNAPOLBLRRK2
SCHEMBL6988596 0.91 CSNK1G1 (0.41) MAPTALDH1A1LMNAPOLBBCKDK
SCHEMBL6996333 0.89 MAPT (0.44) MAPTALDH1A1POLBCDK2CCNE2
SCHEMBL6993425 0.89 MAPT (0.44) MAPTALDH1A1POLBCDK2CCNE2
SCHEMBL6994334 0.88 MDM2 (0.42) ALDH1A1CDK4CCND1MIFMPI
SCHEMBL6993139 0.83 CSNK1G1 (0.38) MAPTALDH1A1POLBLRRK2CASP3
SCHEMBL6998917 0.80 CSNK1G1 (0.46) MAPTALDH1A1LMNAPOLBCDK4
SCHEMBL6994826 0.75 CHEK1 (0.47) MAPTALDH1A1LMNAPOLBBCKDK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP claimed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP claimed
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885ALDH1A1 366/4885LMNA 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.